Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00176943
Status:
COMPLETED
Last Update Posted:
2014-02-14
First Post:
2005-09-12
Brief Title:
Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5
Sponsor:
Hordinsky Maria K MD
Organization:
University of Minnesota
Study Overview
Official Title:
Phenotype and Cytokine Production Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Aldara 5 Cream Using Flow Cytometry
Status:
COMPLETED
Status Verified Date:
2014-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
It is thought that alopecia areata occurs as the result of an inappropriate response of the bodys own immune system to certain substances in or around the hair follicle We will be examining the efficacy of Aldara Cream 5 in treating extensive alopecia areata and observe its affect on the hair follicle
Detailed Description:
We will examine how the application of Aldara Cream 5 daily for 6 months will affect the hair follicle and the inflammation present in the skin of patients with alopecia areata In the study we will obtain additional scalp biopsies to examine how the drug affects the quality and state of activity of the immune cells in the biopsy specimens This type of information will provide data about the behavior of these inflammatory cells in mediating the hair loss associated with alopecia areata and how this behavior may be effected by Aldara Cream 5 treatment Such information may be valuable to the successful management of alopecia areata
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None